Lilly suspends dosing in crucial drug trial

Eli Lilly and its partner Daiichi Sankyo moved swiftly to try and contain any damage from the news that they were suspending dosing in two small trials of the blood clot preventer prasugrel--one of Lilly's most closely watched experimental programs. Officials insisted that the suspension--which was made to consider an adjustment of dosages for certain patients--would have no effect on their development timeline. That wasn't enough for investors, though, who pushed down Lilly's stock by four percent on the news. Prasrugel is considered a key program for Lilly's future, with the potential to compete against the blockbuster Sanofi-Aventis' Plavix--which earned $6 billion last year.

- see Lilly's release on the suspended trial
- check out the report from Forbes

Related Articles:
Lilly pits drug against Plavix in trial. Report
Eli Lilly forges $1B diabetes deal. Report
Daiichi aims for 60 percent growth. Report
In speech, Lilly CEO calls for drug monitoring. Report
Lilly developing biotech drugs the old-fashioned way. Report